Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547179 | 1.00 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL547170 | 0.98 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2A6 | |
| SCHEMBL547155 | 0.97 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL547154 | 0.97 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL547390 | 0.95 | SLC6A4 (0.75) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL912009 | 0.94 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2A6 | |
| SCHEMBL912008 | 0.94 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2A6 | |
| SCHEMBL911774 | 0.91 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL911773 | 0.91 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL548059 | 0.81 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110586-B2 | 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | claimed |
| US-20100267764-A1 | 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2010-10-21 | — | — | US | claimed |
| EP-1948653-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054531-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-05-18 | — | — | WO | claimed |
| US-8110586-B2 | 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | disclosed |
| US-20100267764-A1 | 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2010-10-21 | — | — | US | disclosed |
| EP-1948653-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054531-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267764-A1 | 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC18A3, SLC6A2 | SLC6A4 9/4885SLC6A2 3/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.